β-Ionone inhibits persistent preneoplastic lesions during the early promotion phase of rat hepatocarcinogenesis: TGF-α, NF-κB, and p53 as cellular targets

Nutrition and Cancer

Volumn 66, Issue 2, 2014, Pages 234-241

  Scolastici, Clarissa ^a   De Conti, Aline ^a   Cardozo, Mônica Testoni ^a   Ong, Thomas Prates ^a   Purgatto, Eduardo ^a   Horst, Maria Aderuza ^a   Heidor, Renato ^a   Furtado, Kelly Silva ^a   Bassoli, Bruna Kempfer ^a   Moreno, Fernando Salvador ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

BETA IONONE; CANCER GROWTH FACTOR; CORN OIL; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN P53; SYNAPTOTAGMIN I; TRANSFORMING GROWTH FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CANCER GROWTH; CONTROLLED STUDY; CYTOPLASM; GENE FREQUENCY; GENE TARGETING; IMMUNOHISTOCHEMISTRY; LIVER CARCINOGENESIS; LIVER CELL; LIVER CELL CARCINOMA; LIVER HOMOGENATE; LIVER PROTECTION; MALE; NONHUMAN; PHENOTYPE; PRECANCER; RAT; TARGET CELL; TUMOR PROMOTION;

RATTUS; RATTUS NORVEGICUS; ZEA MAYS;

ANIMALS; ANTICARCINOGENIC AGENTS; CARCINOMA, HEPATOCELLULAR; CHEMOPREVENTION; LIVER; LIVER NEOPLASMS, EXPERIMENTAL; MALE; NF-KAPPA B; NORISOPRENOIDS; RATS; RATS, WISTAR; TRANSFORMING GROWTH FACTOR ALPHA; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84895163467     PISSN: 01635581     EISSN: 15327914     Source Type: Journal    
DOI: 10.1080/01635581.2014.863364     Document Type: Article

References (48)

1. Lachenmayer A, Alsinet C, Chang CY, and Llovet JM: Molecular approaches to treatment of hepatocellular carcinoma. Dig Liver Dis 42, S264-S272, 2010.
2. Bishayee A, Bhatia D, Thoppil RJ, Darvesh AS, Nevo E, et al.: Pomegranate-mediated chemoprevention of experimental hepatocarcinogenesis involves Nrf2-regulated antioxidant mechanisms. Carcinogenesis 32, 888-896, 2011.
3. Sporn MB and Suh N: Chemoprevention of cancer. Carcinogenesis 21, 525-530, 2000. (Pubitemid 30137938)
4. Milner JA: Nutrition and cancer: essential elements for a roadmap. Cancer Lett 269, 189-198, 2008.
5. MoHand Elson CE: Studies of the isoprenoid-mediated inhibition ofmevalonate synthesis applied to cancer chemotherapy and chemoprevention. Exp Biol Med 229, 567-585, 2004.
6. He L, Mo H, Hadisusilo S, Qureshi AA, and Elson CE: Isoprenoids suppress the growth of murine B16 melanomas in vitro and in vivo. J Nutr 127, 668-674, 1997. (Pubitemid 27200738)
7. Liu JR, Sun XR, Dong HW, Sun CH, Sun WG, et al.: β-ionone suppresses mammary carcinogenesis, proliferative activity and induces apoptosis in the mammary gland of the Sprague-Dawley rat. Int J Cancer 122, 2689-2698, 2008.
8. Janakiram NB, Cooma I, Mohammed A, Steele VE, and Rao C: β-ionone inhibits colonic aberrant crypt foci formation in rats, suppresses cell growth, and induces retinoid X receptor-alpha in human colon cancer cells. Mol Cancer Ther 7, 181-190, 2008.
9. Asokkumar S, Naveenkumar C, Raghunandhakumar S, Kamaraj S, Anandakumar P, et al.: Antiproliferative and antioxidant potential of β-ionone against benzo(a)pyrene-induced lung carcinogenesis in Swiss albino mice. Mol Cell Biochem 363, 335-345, 2012.
10. Espíndola RM, Mazzantini RP, Ong TP, de Conti A, Heidor R, et al.: Geranylgeraniol and beta-ionone inhibit hepatic preneoplastic lesions, cell proliferation, total plasma cholesterol and DNA damage during the initial phases of hepatocarcinogenesis, but only the former inhibits NF-kappaB activation. Carcinogenesis 26, 1091-1099, 2005. (Pubitemid 41214302)
11. Cardozo MT, de Conti A, Ong TP, Scolastici C, Purgatto E, et al.: Chemopreventive effects of β-ionone and geraniol during rat hepatocarcinogenesis promotion: distinct actions on cell proliferation, apoptosis, HMGCoA reductase, and RhoA. J Nutr Biochem 22, 130-135, 2011.
12. Bannasch P, Haertel T, and Su Q: Significance of hepatic preneoplasia in risk identification and early detection of neoplasia. Toxicol Pathol 31, 134-139, 2003. (Pubitemid 36169431)
13. Andersen JB, Loi R, Perra A, Factor VM, Ledda-Columbano GM, et al.: Progenitor-derived hepatocellular carcinoma model in the rat. Hepatology 51, 1401-1409, 2010.
14. Petrelli A, Perra A, Schernhuber K, Cargnelutti M, Salvi A, et al.: Sequential analysis of multistage hepatocarcinogenesis reveals that miR-100 and PLK1 dysregulation is an early event maintained along tumor progression. Oncogene 31, 4517-4526, 2012.
15. Semple-Roberts E, Hayes MA, Armstrong D, Becker RA, Racz WJ, and Farber E: Alternative methods of selecting rat hepatocellular nodules resistant to 2-acetylaminofluorene. Int J Cancer 40, 643-645, 1987. (Pubitemid 18003853)
16. Wood GA, Sarma DS, and Archer MC: Resistance to the promotion of glutathione S-transferase 7-7-positive liver lesions in Copenhagen rats. Carcinogenesis 20, 1169-1175, 1999. (Pubitemid 29341435)
17. Heinze T, Jonas S, Karsten A, and Neuhaus P: Determination of the oncogenes p53 and C-erb B2 in the tumour cytosols of advanced hepatocellular carcinoma (HCC) and correlation to survival time. Anticancer Res 19, 2501-2503, 1999. (Pubitemid 29392400)
18. Pires PW, Furtado KS, Justullin Jr L, Rodrigues MAM, Felisbino SL, et al.: Chronic ethanol intake promotes double gluthatione Stransferase/ transforming growth factor-α-positive hepatocellular lesions in male Wistar rats. Cancer Sci 99, 221-228, 2008. (Pubitemid 351228473)
19. Mazzantini RP, de Conti A, and Moreno FS: Persistent and remodeling hepatic preneoplastic lesions present differences in cell proliferation and apoptosis, aswell as in p53, Bcl-2 and NF-kappaB pathways. JCell Biochem 103, 538-546, 2008. (Pubitemid 351171924)
20. Solt DT and Farber E: New principle for the analysis of chemical carcinogenesis. Nature, 263, 702-703, 1976.
21. Su E, Zhang NN, and Ho PC: Determination of tributyrin and its metabolite butyrate in Wistar rat plasma samples by gas chromatography/mass spectrometry. Mass Spectrom 18, 2217-2222, 2004. (Pubitemid 39297356)
22. Wood GA, Sarma DS, and Archer MC: Resistance to the promotion of glutathione S-transferase 7-7-positive liver lesions in Copenhagen rats. Carcinogenesis 20, 1169-1175, 1999. (Pubitemid 29341435)
23. Dragsted LO: Natural antioxidants in chemoprevention. Arch Toxicol Suppl 20, 209-226, 1998.
24. Wattenberg LW: Inhibition of tumorigenesis in animals. IARC Sci Publ 139, 151-181, 1996.
25. Tatematsu M, Nagamine Y, and Farber E: Redifferentiation as a basis for remodeling of carcinogen-induced hepatocyte nodules to normal appearing liver. Cancer Res 43, 5049-5058, 1983. (Pubitemid 14227475)
26. Ledda-Columbano GM, Perra A, Loi R, Shinozuka H, and Columbano A: Cell proliferation induced by triiodothyronine in rat liver is associated with nodule regression and reduction of hepatocellular carcinomas. Cancer Res 60, 603-609, 2000. (Pubitemid 30094557)
27. Pascale RM, Simile MM, De Miglio MR, and Feo F: Chemoprevention of hepatocarcinogenesis: S-adenosyl-L-methionine. Alcohol 27, 193-198, 2002. (Pubitemid 34876922)
28. Simile MM, De Miglio MR, Calvisi D, Muroni M, Frau M, et al.: Longterm dehydroepiandroesterone and 16a-fluoro-5-androsten-17-dione administration enhances DNA synthesis and induces expression of c-fos and c-Ha-ras in a selected population of preneoplastic lesions in liver of diethylnitrosamine- initiated rats. Carcinogenesis 21, 301-308, 2001. (Pubitemid 32175519)
29. Fonseca EMAV, Chagas CEA, Mazzantini RP, Heidor R, Ong TP, et al.: All-trans and 9-cis retinoic acids, retinol and beta-carotene chemopreventive activities during the initial phases of hepatocarcinogenesis involve distinct actions on glutathione S-transferase positive preneoplastic lesions remodeling and DNA damage. Carcinogenesis 26, 1940-1946, 2005. (Pubitemid 41631268)
30. Rizzi MB, Dagli ML, Jordão Jr AA, Penteado MV, and Moreno FS: β-carotene inhibits persistent and stimulates remodeling gamma GT-positive preneoplastic lesions during early promotion of hepatocarcinogenesis. Int J Vitam Nutr Res 67, 415-422, 1997. (Pubitemid 28016993)
31. Goodwin TW:Metabolism, nutrition and function of carotenoids. Annu Rev Nut 6, 273-297, 1986.
32. Ong TP, Moreno FS, and Ross SA: Targeting the epigenome with bioactive food components for cancer prevention. J Nutrigenet Nutrigenomics 4, 275-292, 2011.
33. Pogribny IP and Rusyn I: Role of epigenetic aberrations in the development and progression of human hepatocellular carcinoma. Cancer Lett. foi:http://dx.doi.org/10.1016/j.canlet.2012.01.038
34. Kitano M, Wada J, Ariki Y, Kato M, Wanibuchi H, et al.: Possible tumour development from double positive foci for TGF-alpha and GST-P observed in early stages on rat hepatocarcinogenesis. Cancer Sci 97, 478-483, 2006. (Pubitemid 43811588)
35. Tanno S and Ogawa K:Abundant TGFalpha precursor and EGFreceptor expression as a possible mechanism for the preferential growth of carcinogeninduced preneoplastic and neoplastic hepatocytes in rats. Carcinogenesis 15, 1689-1694, 1994.
36. Coulouarn C, Factor VM, Conner EA, and Thorgeirsson SS: Genomic modeling of tumor onset and progression in a mouse model of aggressive human liver cancer. Carcinogenesis 32, 1434-1440, 2011.
37. Burr AW, Toole K, Mathew J, Hines JE, Chapman C, et al.: Transforming growth factor expression is altered during experimental hepatocarcinogenesis. J Pathol 179, 276-282, 1996. (Pubitemid 26266406)
38. Dias CD, Rodrigues MAM, Reimberg MCH, and Barbisan LF: Protective effects of Ginkgo biloba against rat liver carcinogenesis. Chem Biol Interact 173, 32-42, 2008.
39. Carrasco-Legleu CE, Marquez-Rosado L, Fattel-Fazenda S, Arce-Popoca E, Perez-Carreon JI, et al.: Chemoprotective effect of caffeic acid phenethyl ester on promotion in a medium-term rat hepatocarcinogenesis assay. Int J Cancer 108, 488-492, 2004. (Pubitemid 38036647)
40. Sato Y, Kato J, Takimoto R, Takada K, Kawano Y, et al.: Hepatitis C vírus core protein promotes proliferation of human hepatoma cells through enhancement of transforming growth fator alpha expression via activation of nuclear factor-kappa B. Gut 55, 381-389, 2006.
41. Brechbuhl HM, Kachadourian R, Min E, Chan D, and Day BJ: Chrysin enhances doxorubicin-induced cytotoxicity in human lung epithelial cancer cell lines. The role of glutathione. Toxicol Appl Pharmacol 10, 1-9, 2011.
42. Plummer SM, Holloway KA, Manson MM, Munks RJ, Kaptein A, et al.: Inhibition of cyclo-oxygenase 2 expression in colon cells by the chemopreventive agent curcumin involves inhibition of NF-kappaB activation via the NIK/IKK signalling complex. Oncogene 18, 6013-6020, 1999. (Pubitemid 29535013)
43. Banerjee S, Bueso-Ramos C, and Aggarwal BB: Suppression of 7,12 imethylbenz(a)anthracene-induced mammary carcinogenesis in rats by resveratrol: role of nuclear factor-kappaB, cyclooxygenase 2, and matrix metalloprotease 9. Cancer Res 62, 4945-4954, 2002. (Pubitemid 34984418)
44. Zaika A, Marchenko N, and Moll UM: Cytoplasmically " sequestered" wild type p53 protein is resistant to mdm2-mediated degradation. J Biol Chem 274, 774-780, 1999.
45. Kiss A, Wang NJ, Xie JP, and Thorgeirsson SS: Analysis of transforming growth factor (TGF)-alpha/epidermal growth factor receptor, hepatocyte growth Factor/c-met, TGF-beta receptor type II, and p53 expression in humam hepatocellular carcinomas. Clin Cancer Res 3, 1059-1066, 1997. (Pubitemid 27319751)
46. Kuroiwa-Trzmielina J, de Conti A, Scolastici C, Pereira D, Horst MA, et al.: Chemoprevention of rat hepatocarcinogenesis with histone deacetylase inhibitors: Efficacy of tributyrin, a butyric acid prodrug. Int J Cancer 124, 2520-2527, 2009.
47. Van Gijssel HE, Ohlson LCE, Torndal UB, Mulder GJ, Eriksson LC, et al.: Loss of nuclear p53 protein in preneoplastic rat hepatocytes is accompanied by Mdm2 and Bcl-2 overexpression and by defective response to DNA damage in vivo. Hepatology 32, 701-710, 2000.
48. Fabbro Mand Henderson BR: Regulation of tumor suppressors by nuclearcytoplasmic shuttling. Exp Cell Res 282, 59-69, 2003.